Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial

被引:496
作者
Paz-Ares, Luis [1 ]
de Marinis, Filippo [2 ]
Dediu, Mircea [3 ]
Thomas, Michael [4 ]
Pujol, Jean-Louis [5 ]
Bidoli, Paolo [6 ]
Molinier, Olivier [7 ]
Sahoo, Tarini Prasad [8 ]
Laack, Eckart [9 ]
Reck, Martin [10 ]
Corral, Jesus
Melemed, Symantha [11 ]
John, William [11 ]
Chouaki, Nadia [12 ]
Zimmermann, Annamaria H. [11 ]
Visseren-Grul, Carla [13 ]
Gridelli, Cesare [14 ]
机构
[1] Univ Seville, Univ Hosp Virgen del Rocio, Med Oncol Serv, Inst Biomed Sevilla, Av Manuel Siurot, Seville 41013, Spain
[2] San Camillo Forlanini Hosp, Rome, Italy
[3] Inst Oncol Bucharest, Bucharest, Romania
[4] Heidelberg Univ, Thoraxklin, Heidelberg, Germany
[5] Montpellier CHRU Acad Hosp, Montpellier, France
[6] S Gerardo Hosp, Med Oncol Unit, Monza, Italy
[7] Le Mans Reg Hosp, Le Mans, France
[8] Jawaharlal Nehru Canc Hosp & Res Ctr, Bhopal, India
[9] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany
[10] Hosp Grosshansdorf, Grosshansdorf, Germany
[11] Eli Lilly & Co, Indianapolis, IN 46285 USA
[12] Eli Lilly & Co, Suresnes, Hauts De Seine, France
[13] Eli Lilly & Co, Houten, Netherlands
[14] San Giuseppe Moscati Hosp, Avellino, Italy
关键词
1ST-LINE CHEMOTHERAPY; TREATMENT RATIONALE; TREATMENT OPTIONS; III TRIAL; BEVACIZUMAB; GEMCITABINE; CARBOPLATIN; GUIDELINES; DOCETAXEL; EFFICACY;
D O I
10.1016/S1470-2045(12)70063-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Patients with advanced non-squamous non-small-cell lung cancer (NSCLC) benefit from pemetrexed maintenance therapy after induction therapy with a platinum-containing, non-pemetrexed doublet. The PARAMOUNT trial investigated whether continuation maintenance with pemetrexed improved progression-free survival after induction therapy with pemetrexed plus cisplatin. Methods In this double-blind, multicentre, phase 3, randomised placebo-controlled trial, patients with advanced non-squamous NSCLC aged 18 years or older, with no previous systemic chemotherapy for lung cancer, with at least one measurable lesion, and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 participated. Before randomisation, patients entered an induction phase which consisted of four cycles of induction pemetrexed (500 mg/m(2)) plus cisplatin (75 mg/m(2)) on day 1 of a 21-day cycle. Patients who did not progress after completion of four cycles of induction and who had an ECOG performance status of 0 or 1 were stratified according to disease stage (IIIB or IV), ECOG performance status (0 or 1), and induction response (complete or partial response, or stable disease), and randomly assigned (2: 1 ratio) to receive maintenance therapy with either pemetrexed (500 mg/m(2) every 21 days) plus best supportive care or placebo plus best supportive care until disease progression. Randomisation was done with the Pocock and Simon minimisation method. Patients and investigators were masked to treatment assignment. The primary endpoint was progression-free survival in the intention-to-treat population. This study is registered with ClinicalTrials.gov, NCT00789373. Findings Of the 1022 patients enrolled, 939 participated in the induction phase. Of these, 539 patients were randomly assigned to receive continuation maintenance with pemetrexed plus best supportive care (n=359) or with placebo plus best supportive care (n=180). Among the 359 patients randomised to continuation maintenance with pemetrexed, there was a significant reduction in the risk of disease progression over the placebo group (HR 0.62, 95% CI 0.49-0.79; p<0.0001). The median progression-free survival, measured from randomisation, was 4.1 months (95% CI 3.2-4.6) for pemetrexed and 2.8 months (2.6-3.1) for placebo. Possibly treatment-related laboratory grade 3-4 adverse events were more common in the pemetrexed group (33 [9%] of 359 patients) than in the placebo group (one [<1%] of 180 patients; p<0.0001), as were non-laboratory grade 3-5 adverse events (32 [9%] of 359 patients in the pemetrexed group; eight [4%] of 180 patients in the placebo group; p=0.080); one possibly treatment-related death was reported in each group. The most common adverse events of grade 3-4 in the pemetrexed group were anaemia (16 [4%] of 359 patients), neutropenia (13 [4%]), and fatigue (15 [4%]). In the placebo group, these adverse events were less common: anaemia (one [<1%] of 180 patients), neutropenia (none), and fatigue (one [<1%]). The most frequent serious adverse events were anaemia (eight [2%] of 359 patients in the pemetrexed group vs none in the placebo group) and febrile neutropenia (five [1%] vs none). Discontinuations due to drug-related adverse events occurred in 19 (5%) patients in the pemetrexed group and six (3%) patients in the placebo group. Interpretation Continuation maintenance with pemetrexed is an effective and well tolerated treatment option for patients with advanced non-squamous NSCLC with good performance status who have not progressed after induction therapy with pemetrexed plus cisplatin.
引用
收藏
页码:247 / 255
页数:9
相关论文
共 30 条
  • [11] Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    D'Addario, G.
    Frueh, M.
    Reck, M.
    Baumann, P.
    Klepetko, W.
    Felip, E.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : v116 - v119
  • [12] Phase III Study of Immediate Compared With Delayed Docetaxel After Front-Line Therapy With Gemcitabine Plus Carboplatin in Advanced Non-Small-Cell Lung Cancer
    Fidias, Panos M.
    Dakhil, Shaker R.
    Lyss, Alan P.
    Loesch, David M.
    Waterhouse, David M.
    Bromund, Jane L.
    Chen, Ruqin
    Hristova-Kazmierski, Maria
    Treat, Joseph
    Obasaju, Coleman K.
    Marciniak, Martin
    Gill, John
    Schiller, Joan H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (04) : 591 - 598
  • [13] Fleming ID, 1997, AJCC Cancer Staging Manual, V5th, P127
  • [14] Potential Treatment Options After First-Line Chemotherapy for Advanced NSCLC: Maintenance Treatment or Early Second-Line?
    Gridelli, Cesare
    Maione, Paolo
    Rossi, Antonio
    Ferrara, Marianna Luciana
    Bareschino, Maria Anna
    Schettino, Clorinda
    Sacco, Paola Claudia
    Ciardiello, Fortunato
    [J]. ONCOLOGIST, 2009, 14 (02) : 137 - 147
  • [15] Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy
    Hanna, N
    Shepherd, FA
    Fossella, FV
    Pereira, JR
    De Marinis, F
    von Pawel, J
    Gatzemeier, U
    Tsao, TCY
    Pless, M
    Muller, T
    Lim, HL
    Desch, C
    Szondy, K
    Gervais, R
    Shaharyar
    Manegold, C
    Paul, S
    Paoletti, P
    Einhorn, L
    Bunn, PA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (09) : 1589 - 1597
  • [16] NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS
    KAPLAN, EL
    MEIER, P
    [J]. JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) : 457 - 481
  • [17] TOXICITY AND RESPONSE CRITERIA OF THE EASTERN-COOPERATIVE-ONCOLOGY-GROUP
    OKEN, MM
    CREECH, RH
    TORMEY, DC
    HORTON, J
    DAVIS, TE
    MCFADDEN, ET
    CARBONE, PP
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1982, 5 (06): : 649 - 655
  • [18] Treatment Rationale and Study Design for the PointBreak Study: A Randomized, Open-label Phase III Study of Pemetrexed/Carboplatin/Bevacizumab Followed by Maintenance Pemetrexed/Bevacizumab Versus Paclitaxel/Carboplatin/Bevacizumab Followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non-Small-Cell Lung Cancer
    Patel, Jyoti D.
    Bonomi, Philip
    Socinski, Mark A.
    Govindan, Ramaswamy
    Hong, Shengyan
    Obasaju, Coleman
    Pennella, Eduardo J.
    Girvan, Allicia C.
    Guba, Susan C.
    [J]. CLINICAL LUNG CANCER, 2009, 10 (04) : 252 - 256
  • [19] Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer
    Paz-Ares, Luis G.
    Altug, Sedat
    Vaury, Alexandra Thareau
    Corral Jaime, Jesus
    Russo, Francesca
    Visseren-Grul, Carla
    [J]. BMC CANCER, 2010, 10
  • [20] Maintenance with either gemicitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFC-GFPC 0502 phase III study
    Perol, M.
    Chouaid, C.
    Milleron, B. J.
    Gervais, R.
    Barlesi, F.
    Westeel, V.
    Crequit, J.
    Lena, H.
    Vergnenegre, A.
    Perol, D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)